-
The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes: Cannabis may have a greater impact in non-tobacco smokers.
Winhusen TJ, Theobald J, Kaelber DC, Lewis D. The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes: Cannabis may have a greater impact in non-tobacco smokers. American Journal of Drug and Alcohol Abuse 2020;46(4):454-461
-
Altered monocyte phenotype and dysregulated innate cytokine responses among people living with HIV and opioid-use disorder.
Underwood ML, Nguyen T, Uebelhoer LS, Kunkel LE, Korthuis PT, Lancioni CL. Altered monocyte phenotype and dysregulated innate cytokine responses among people living with HIV and opioid-use disorder. AIDS 2020;34:177-188.
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-acetylcysteine for adult cannabis use disorder.
Tomko RL, Baker NL, Hood CO, Gilmore AK, McClure EA, Squeglia LM, McRae-Clark AL, Sonne SC, Gray KM. Depressive symptoms and cannabis use in a placebo-controlled trial of N-acetylcysteine for adult cannabis use disorder. Psychopharmacology 2020;237(2):479-490.
-
A systematic scoping review of research on Black participants in the National Drug Abuse Treatment Clinical Trials Network.
Montgomery L, Burlew AK, Haeny AM, Jones CA. A systematic scoping review of research on Black participants in the National Drug Abuse Treatment Clinical Trials Network. Psychology of Addictive Behaviors 2020;34(1):117-127.
-
Integration of screening, assessment, and treatment for cannabis and other drug use disorders in primary care: An evaluation in three pilot sites.
Richards JE, Bobb JF, Lee AK, Lapham GT, Williams EC, Glass JE, Ludman EJ, Achtmeyer C, Caldeiro RM, Oliver M, Bradley KA. Integration of screening, assessment, and treatment for cannabis and other drug use disorders in primary care: An evaluation in three pilot sites. Drug and Alcohol Dependence 2019;201:134-141.
-
Making measurement-based care for addictions a reality in primary care [commentary].
Bradley KA, Caldeiro RM, Hallgren KA, Kivlahan DR. Making measurement-based care for addictions a reality in primary care [commentary]. Addiction 2019;114(8):1355-1356.
-
Factors associated with Healthcare Effectiveness Data and Information Set (HEDIS) alcohol and other drug measure performance in 2014-2015.
Weisner C, Campbell CI, Altschuler A, Yarborough BJH, Lapham GT, Binswanger IA, Hechter RC, Ahmedani BK, Haller IV, Sterling SA, McCarty D, Satre DD, Kline-Simon AH. Factors associated with Healthcare Effectiveness Data and Information Set (HEDIS) alcohol and other drug measure performance in 2014-2015. Substance Abuse 2019;40(3):318-327.
-
Tobacco cessation services in addiction treatment: What do clients say?
Guydish JR, Yip D, Le T, Gubner NR, Williams DD, Delucchi KL. Tobacco cessation services in addiction treatment: What do clients say? Psychiatric Services 2019;70:229-232
-
A 3’ UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addiction.
Levran O, Randesi M, Rotrosen J, Ott J, Adelson M, Kreek MJ. A 3’ UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addiction. PLoS ONE 2019;14(11): e0224399
-
Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial.
Hoffman KA, Baker R, Kunkel LE, Waddell EN, Lum PJ, McCarty D, Korthuis PT. Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. BMC Health Services Research 2019;19:862.